Low-dose digoxin is being evaluated for its efficacy and safety in improving outcomes for patients with heart failure and reduced or mildly reduced ejection fraction.
Does low-dose digoxin improve outcomes in patients with HFrEF and HFmrEF?
The DECISION trial will provide evidence on the efficacy and safety of low-dose digoxin in contemporary patients with HFrEF and HFmrEF.
Absolute Event Rate: 0% vs 0%
DECISION enrolled a contemporary and well-treated population of patients with HFrEF and HFmrEF and will provide important evidence regarding the efficacy and safety of low-dose digoxin on outcome in patients with reduced or mildly reduced LVEF.
Meer et al. (Thu,) reported a other. Low-dose digoxin is being evaluated for its efficacy and safety in improving outcomes for patients with heart failure and reduced or mildly reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: